ZEB2

Across TCGA pan-cancer cohorts, ZEB2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ZEB2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where ZEB2 RNA is repressed in tumor relative to normal tissue. In most cancer types ZEB2 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, KIRC, and COAD are the cancer types where ZEB2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZEB2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	−1.881	<.001	11	view →
KIRC	Male	IV	+1.037	<.001	11	view →
COAD	Female	II,III,IV	−1.147	<.001	10	view →
LUSC	Female	All	−1.911	<.001	9	view →
UCEC	All	All	−2.146	<.001	8	view →
KICH	Female	All	−1.757	<.001	8	view →
LUAD	Female	III,IV	−1.530	<.001	8	view →
HNSC	Female	All	+0.882	.002	7	view →
THCA	All	II,III,IV	−0.724	<.001	7	view →
BRCA	All	III,IV	−1.015	<.001	6	view →
READ	Female	All	−1.842	.004	2	view →
PRAD	All	All	−0.545	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ZEB2–BLCA

Open the BLCA breakdown →